1
|
Mayeur A, Magnan F, Mathieu S, Rubens P, Sperelakis Beedham B, Sonigo C, Steffann J, Frydman N. What importance do donors and recipients attribute to the nuclear DNA-related genetic heritage of oocyte donation? Hum Reprod 2024; 39:770-778. [PMID: 38420661 DOI: 10.1093/humrep/deae030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 01/31/2024] [Indexed: 03/02/2024] Open
Abstract
STUDY QUESTION How do oocyte donors and recipients perceive the genetic link related to the transfer of nuclear DNA between donors and offspring? SUMMARY ANSWER Whether they are donors or recipients, individuals attach great importance to the transmission of their genetic heritage, since 94.5% would opt for the pronuclear transfer method to preserve this genetic link in the context of oocyte donation. WHAT IS KNOWN ALREADY Since 1983, the use of oocyte donation has increased worldwide. Performed in France since the late 1980s and initially offered to women with premature ovarian insufficiency, its indications have progressively expanded and now it is proposed in many indications to prevent the transmission of genetically inherited diseases. This has resulted in an increase in the waiting time for access to oocyte donation due to the difficulty in recruiting oocyte donors in French ART centres. Several articles have discussed how to fairly distribute donor oocytes to couples, but few have interviewed women in the general population to record their feelings about oocyte donation, as either the donor or recipient and the importance given to the genetic link between the oocyte donors and the children born. Mitochondrial replacement therapy (MRT) is a technique originally developed for women at risk of transmitting a mitochondrial DNA mutation. Recently, MRT has been considered for embryo arrest and oocyte rejuvenation as it could help females to reproduce with their own genetic material through the transfer of their oocyte nucleus into a healthy donor oocyte cytoplasm. STUDY DESIGN, SIZE, DURATION We conducted an opinion survey from January 2021 to December 2021, during which 1956 women completed the questionnaire. Thirteen participants were excluded from the analysis due to incomplete responses to all the questions. Consequently, 1943 women were included in the study. PARTICIPANTS/MATERIALS, SETTING, METHODS We specifically developed a questionnaire for this study, which was created and distributed using the Drag'n Survey® software. The questionnaire consisted of 21 items presented alongside a video created with whiteboard animation software. The aim was to analyse whether certain factors, such as age, education level, marital status, number of children, use of ART for pregnancy, video viewing, and knowledge about oocyte donation, were associated with feelings towards oocyte donation, by using a univariate conditional logistic regression model. This statistical method was also used to assess whether women would be more inclined to consider oocyte donation with the pronuclear transfer technique rather than the whole oocyte donation. All parameters found to be statistically significant in the univariate analysis were subsequently tested in a multivariate model using logistic regression. MAIN RESULTS AND THE ROLE OF CHANCE Most women were concerned about the biological genetic contribution of the donated oocyte (94.8%). The most common reason for a women's reluctance to donate their oocytes was their unwillingness to pass on their genetic material (33.3%). Nearly 70% of women who were initially hesitant to donate their oocytes indicated that they would reconsider their decision if the oocyte donation was conducted using donated cytoplasm and the pronuclear transfer technique. Concomitantly, >75% of the respondents mentioned that it would be easier to receive a cytoplasm donation. The largest proportion of the population surveyed (94.5%) expressed their support for its legalization. LIMITATIONS, REASONS FOR CAUTION In this study, a substantial portion of the responses came from individuals with medical or paramedical backgrounds, potentially introducing a recruitment bias among potential donors. The rate of missing responses to the question regarding the desire to become an oocyte donor was 13.6%, while the question about becoming an oocyte cytoplasm donor had a missing response rate of 23%. These missing responses may introduce a bias in the interpretation of the data. WIDER IMPLICATIONS OF THE FINDINGS This study was the first to demonstrate that, for the French population studied, the combination of oocyte cytoplasm donation with pronuclear transfer could offer a promising approach to enhance the acceptance of oocyte donation for both the donor and the recipient. STUDY FUNDING/COMPETING INTEREST(S) No external funding was used for this study. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- A Mayeur
- Service de Biologie de la Reproduction-CECOS, Assistance Publique Hôpitaux de Paris, Hôpital Antoine Béclère, Clamart, France
- Université de Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - F Magnan
- Service de Biologie de la Reproduction-CECOS, Assistance Publique Hôpitaux de Paris, Hôpital Antoine Béclère, Clamart, France
| | - S Mathieu
- École Pratique des Hautes Études (EPHE), Paris Sciences Lettres (PSL), GSRL UMR8582, Paris, France
| | - P Rubens
- Service de Médecine Génomique des Maladies rares, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades, Paris, France
- Université Paris Cité, Institut Imagine, INSERM UMR1163, Paris, France
| | - B Sperelakis Beedham
- Service de Médecine Génomique des Maladies rares, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades, Paris, France
| | - C Sonigo
- Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Saclay, Service de Médecine de la Reproduction et Préservation de la Fertilité, Hôpital Antoine Béclère, Clamart, France
- France Université Paris Saclay, Inserm, Physiologie et physiopathologie endocrinienne, Le Kremlin-Bicêtre, France
| | - J Steffann
- Service de Médecine Génomique des Maladies rares, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades, Paris, France
- Université Paris Cité, Institut Imagine, INSERM UMR1163, Paris, France
| | - N Frydman
- Service de Biologie de la Reproduction-CECOS, Assistance Publique Hôpitaux de Paris, Hôpital Antoine Béclère, Clamart, France
- Université de Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| |
Collapse
|
2
|
Tammaccaro SL, Prigent P, Le Bail JC, Dos-Santos O, Dassencourt L, Eskandar M, Buzy A, Venier O, Guillemot JC, Veeranagouda Y, Didier M, Spanakis E, Kanno T, Cesaroni M, Mathieu S, Canard L, Casse A, Windenberger F, Calvet L, Noblet L, Sidhu S, Debussche L, Moll J, Valtingojer I. TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. Pharmaceuticals (Basel) 2023; 16:ph16040553. [PMID: 37111311 PMCID: PMC10142471 DOI: 10.3390/ph16040553] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 03/23/2023] [Accepted: 03/29/2023] [Indexed: 04/08/2023] Open
Abstract
KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRASG12C mutant NSCLC; however, resistance to therapy is emerging. The transcriptional coactivators YAP1/TAZ and the family of transcription factors TEAD1-4 are the downstream effectors of the Hippo pathway and regulate essential cellular processes such as cell proliferation and cell survival. YAP1/TAZ-TEAD activity has further been implicated as a mechanism of resistance to targeted therapies. Here, we investigate the effect of combining TEAD inhibitors with KRASG12C inhibitors in KRASG12C mutant NSCLC tumor models. We show that TEAD inhibitors, while being inactive as single agents in KRASG12C-driven NSCLC cells, enhance KRASG12C inhibitor-mediated anti-tumor efficacy in vitro and in vivo. Mechanistically, the dual inhibition of KRASG12C and TEAD results in the downregulation of MYC and E2F signatures and in the alteration of the G2/M checkpoint, converging in an increase in G1 and a decrease in G2/M cell cycle phases. Our data suggest that the co-inhibition of KRASG12C and TEAD leads to a specific dual cell cycle arrest in KRASG12C NSCLC cells.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Armelle Buzy
- Bio Structure and Biophysics, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Olivier Venier
- Small Molecules Medicinal Chemistry, Sanofi R&D, 91380 Chilly-Mazarin, France
| | - Jean-Claude Guillemot
- Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France
| | - Yaligara Veeranagouda
- Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France
| | - Michel Didier
- Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France
| | | | - Tokuwa Kanno
- Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Matteo Cesaroni
- Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Stephane Mathieu
- Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Luc Canard
- Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Alhassan Casse
- Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | - Fanny Windenberger
- Non-Clinical Efficacy and Safety, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | | | | | | | | | - Jurgen Moll
- Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France
| | | |
Collapse
|
3
|
Tammaccaro S, Prigent P, Le Bail J, Santos OD, Dassencourt L, Picard-Vernier P, Eskandar M, Buzy A, Guillemot JC, Veeranagouda Y, Didier M, Spanakis E, Kanno T, Cesaroni M, Mathieu S, Canard L, Casse A, Debussche L, Moll J, Valtingojer I. 80P Dual cell cycle arrest in KRAS mutant cell lines by co-inhibition of MAPK and Hippo-YAP1 pathways. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Squercioni B, Pereira B, Beauger M, Couderc M, Ladouce F, Malochet S, Mathieu S, Marie-Eva P, Soubrier M, Tournadre A. POS0587 TRAJECTORIES AND FACTORS INFLUENCING THE EVOLUTION OF HAND GRIP AMONG PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRheumatoid arthritis (RA) is characterized by an early reduced grip strength which persists over time despite the remission of the disease suggesting the presence of a sarcopenia.ObjectivesTo study the evolution of the grip strength measured by the handgrip. by identifying different trajectories and associated factors.MethodsPatients with active RA who visited the Rheumatology Department of Clermont-Ferrand University Hospital for initiating bDMARD were invited to participate to the longitudinal cohort RCVRIC analyzing cardiovascular risk and chronic inflammatory rheumatic disease. Within the RCVRIC cohort 175 RA initially underwent a handgrip determination. 143 patients had at least 2 handgrip measurements over 2 years, allowing analysis of trajectories by the “Group Based Trajectory Modeling” method. For the trajectories, handgrip was expressed in terms of percentage of the theoretical value defined according to age and sex. The clinical characteristics of the disease, the therapeutic response, and the body composition associated with each trajectory were analyzed.ResultsAt inclusion, the handgrip was normal among only 4% of patients, with an alteration of 51% of its theoretical value. After 2 years of follow-up, a majority of patients improved their handgrip trajectory to reach an average of 68% of the theoretical one, but only 15.7% of the patients normalized their handgrip. Four trajectories have been identified along with associated factors:1st trajectory consists of low handgrip with little improvement and was composed of: 9 patients (6.3%), median age 60 years [53.6;69.3], 88% women, disease duration 17.99 years [6.78;24.9], DAS 28 ESR 4.68 ± 1.29, and initial handgrip 21% of the theoretical value [8;24].2nd trajectory shows good improvement (+72%) and was composed of: 70 patients (49%), median age 58.9 years [54.4;64.3], 84% women, disease duration 5.99 years [1.46;14.8], DAS 28 ESR 4.43 ± 1.07, and initial handgrip 32% of the theoretical value [17.8;46.4].3rd trajectory shows moderate improvement (+25%) and was composed of: 43 patients (30%), median aged 60.7 years [45.7;69.4], 79% women, disease duration 3.5 years [1.25;9.9], DAS 28 ESR 4.0 ± 1.03 and initial handgrip 60% of the theoretical value [48.2;76].4th trajectory shows high handgrip and was composed of: 21 patients (14.7%), 57% women, median age 57.9 years old [49.7; 67.4], disease duration 3.81 years [2.14; 10.7], DAS 28 ESR 3.68 ±1.29 and initial hand grip 92% of the theoretical value [85; 100].Significant differences at inclusion between the 4 trajectories were observed. The 4th trajectory was characterized by a higher proportion of men (p=0.05), lower disease activity (DAS 28 ESR (p=0.02), SDAI (p=0.04)), better initial handgrip (p=0.03) and 6 min walk test (p=0.0001), and a lower percentage of fat mass (p=0.04). In contrast, a higher disability (HAQ, p=0.002), a lower total lean body mass (p=0.001) and poorer therapeutic response (p=0.04) were noted in trajectories 1 and 2.ConclusionAfter 2 years of follow-up, a majority of patients improved their handgrip trajectory. However, very few patients normalized their hand grip. Four trajectories of handgrip were identified; the main indicators of hand grip’s improvement were the control of the disease activity, low functional disability, walking performance, a low percentage of fat mass and high lean mass.References[1]Cruz-Jentoft AJ, and al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. janv 2019[2]An HJ, and al. Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review. Int J Mol Sci. 7 août 2020[3]Shiratori AP and al. Evaluation protocols of hand grip strength in individuals with rheumatoid arthritis: systematic review. Rev Bras Reumatol. avr 2014[4]Dodds RM, et al. Grip strength across the life course: normative data from twelve British studies. PloS One. 2014;AcknowledgementsI thank the department of rheumatology of Clermont Ferrand.Disclosure of InterestsNone declared.
Collapse
|
5
|
Guiot J, Vaidyanathan A, Zerka F, Deprez L, Danthine D, Frix AN, Bottari F, Henket M, Mathieu S, Lambin P, Walsh S, Occhipinti M, Misset B, Renard L, Meunier P, Vos W, Leijenaar RT, Lovinfosse P, This Work Has Received Support From The Eu/ef. Prediction of outcome in COVID-19 patients based on clinical and radiomics chest CT data. Imaging 2021. [DOI: 10.1183/13993003.congress-2021.pa361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
6
|
Mathieu S, Dorard G. Végétarisme, végétalisme, véganisme : des comportements (alimentaires) au service de l’identité ? Une étude qualitative en population française. Psychologie Française 2021. [DOI: 10.1016/j.psfr.2020.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Stoffel B, McPherson M, Hernandez A, Goess C, Mathieu S, Waegell W, Bryant S, Hobson A, Ruzek M, Pang Y, Kupper H, D’Cunha R, Parmentier J, Radstake T. POS0365 ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2213] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Glucocorticoids (GC) are potent drugs used for treating many inflammatory diseases. While GCs are effective in many immune diseases, dose and duration of administration is limited due to significant side effects. Resting immune cells have very little TNF expression on the cell surface and it is only in an activated state that TNF expression is upregulated. Upon immune cell stimulation, TNF is upregulated and although a significant amount of TNF is cleaved from an activated cell, a portion remains on the cell surface. We have observed that anti-TNF antibodies bind to transmembrane TNF (tmTNF) and undergo endocytosis to the lysosome (1). We have developed a stable antibody drug conjugate (ADC), ABBV-3373, that has a proprietary, highly potent, glucocorticoid receptor modulator (GRM) payload linked to an anti-TNF monoclonal antibody (mAb) that is able to deliver the GC payload to activated immune cells.Objectives:We hypothesized that a TNF ADC with a GRM payload would be able to deliver increased efficacy through both TNF inhibition and targeted GRM payload delivery to activated immune cells while sparing systemic glucocorticoid side effects.Methods:A mouse surrogate TNF GRM ADC was characterized in an acute in vivo contact hypersensitivity model of inflammation (CHS) and in a mouse model of collagen induced arthritis (mCIA). Additionally, the human anti-TNF GRM ADC, ABBV-3373 has been characterized in healthy volunteers.Results:In the CHS model the anti-TNF GRM ADC significantly inhibited the inflammatory response with minimal effect on systemic GC biomarkers. In mCIA a single dose of an anti-TNF GRM ADC, administered at disease onset, was able to completely inhibit arthritis for greater than 30 days while an anti-TNF mAb only partially inhibited disease. ABBV-3373, a human anti-TNF GRM ADC with a GC payload, was evaluated in a Phase 1 study in healthy volunteers. ABBV-3373 demonstrated antibody-like PK profile and ABBV-3373 did not impact cortisol levels at predicted efficacious doses while control subjects that received a single oral dose of 10 mg prednisone demonstrated expected decreases in cortisol levels.Conclusion:These data suggest that an anti-TNF ADC delivering a GRM payload into activated immune cells may provide improved efficacy in immune mediated diseases, while minimizing systemic side effects associated with standard GC treatment.References:[1]Deora, A. et al. MABs. 2017;9(4):680-695.Disclosure of Interests:Bob Stoffel Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Michael McPherson Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Axel Hernandez Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Christian Goess Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Suzanne Mathieu Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Wendy Waegell Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Shaughn Bryant Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Adrian Hobson Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Melanie Ruzek Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Yinuo Pang Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Hartmut Kupper Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Ronilda D’Cunha Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Julie Parmentier Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie, Timothy Radstake Shareholder of: AbbVie, Grant/research support from: AbbVie, Employee of: AbbVie
Collapse
|
8
|
Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology (Oxford) 2021; 60:549-556. [PMID: 33159797 DOI: 10.1093/rheumatology/keaa534] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 07/24/2020] [Accepted: 07/24/2020] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVES Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic DMARDs in RA, patients remain in pain and often turn to non-prescribed pharmacological alternatives, such as cannabis self-therapeutic use. However, this medical use of cannabis has not been thoroughly studied. METHODS We performed a systematic literature review up to June 2020. The incidence of cannabis consumption was calculated by metaproportion. Differences between cannabis users and non-users were expressed as standardized mean differences using the inverse-variance method. We also assessed the effects of cannabis on pain. RESULTS A total of 2900 patients reported cannabis consumption in a sample of 10 873 patients [incidence 40.4% (95% confidence interval (CI): 0.28, 0.54)], and 15.3% (95% CI: 0.07, 0.27) specified that they were currently taking cannabis. Cannabis use was higher in the four fibromyalgia studies [68.2% (95% CI: 0.41, 0.90), n = 611] compared with seven articles concerning RA or lupus [26.0% (95% CI: 0.14, 0.41), n = 8168]. Cannabis consumption was associated with a decrease in pain intensity [VAS pain at baseline 8.2 (2.9) vs 5.6 (3.5) mm over time; pooled effect size -1.75 (95% CI: -2.75, -0.76)]. Cannabis users were younger [58.4 (11.4) vs 63.6 (12.1) years; P <0.001], more often smokers [OR 2.91 (95% CI: 1.84, 4.60)] or unemployed [OR 2.40 (95% CI: 1.31, 4.40)], and had higher pain intensity [5.0 (2.4) vs 4.1(2.6) mm; P <0.001] than non-users. CONCLUSION Nearly 20% of patients suffering from rheumatologic diseases actively consume cannabis, with an improvement in pain. The issue of cannabis use in the management of these patients should be addressed during medical consultation, essentially with cannabis-based standardized pharmaceutical products.
Collapse
Affiliation(s)
- M Guillouard
- Rheumatology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - N Authier
- Université Clermont Auvergne, UMR INSERM 1107, CHU, Clermont-Ferrand, France.,Institut ANALGESIA, Faculté de Médecine, Clermont-Ferrand, France.,Observatoire Français des Médicaments Antalgiques (OFMA), French Monitoring Centre for Analgesic Drugs, CHU, Clermont-Ferrand, France
| | - B Pereira
- Biostatistics Unit (Clinical Research Direction), University Hospital of Clermont-Ferrand (CHU), Clermont-Ferrand, France
| | - M Soubrier
- Rheumatology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - S Mathieu
- Rheumatology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| |
Collapse
|
9
|
Mathieu S, Pereira B, Saraux A, Richez C, Combe B, Soubrier M. Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort. Rheumatol Int 2021; 41:879-885. [PMID: 33433729 DOI: 10.1007/s00296-020-04770-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 12/08/2020] [Indexed: 10/22/2022]
Abstract
Physicians are sometimes hesitant to use disease-modifying antirheumatic drugs (DMARDs) in elderly patients with rheumatoid arthritis (RA), as they are deemed too fragile, although there are no sufficient scientific evidence. We aimed to compare DMARD treatment retention in early RA patients from the ESPOIR cohort, according to age upon inclusion. Overall, treatment retention was evaluated as the percentage of patients whose DMARDs were not stopped, with stratification by age group: < 50, 50-64, and > 65 years. Survival curves were measured using the Kaplan-Meier method. Of the entire ESPOIR cohort (n = 813), 7% were > 65 years old. Methotrexate (MTX) was used by 521 patients, and was the sole DMARD for 198 patients. MTX treatment retention appeared better in patients > 65 years old compared to < 50 years old [HR 0.45 (0.25; 0.81); p = 0.008, n = 195/198] with adjustment on sex, smoking, positive anti-cyclic citrullinated peptide antibodies, positive rheumatoid factor, body mass index, changes in DAS28 and corticosteroid treatment. The proportion of patients using etanercept (n = 111), and this drug's retention rate, did not differ according to patient age. The proportion of patients treated with adalimumab (n = 104) was significantly higher in patients < 50 years old (p = 0.003), and treatment retention was marginally better among younger patients [HR 1.68 (0.88; 3.22), p = 0.12]. Within the ESPOIR cohort, DMARD retention did not appear to differ according to age-except for better retention of MTX treatment in patients 50-64 years old, and of adalimumab in patients < 50 years old.
Collapse
Affiliation(s)
- S Mathieu
- Rheumatology Department, CHU Gabriel Montpied, Clermont 1 University, Clermont-Ferrand, France.
| | - B Pereira
- Department of Clinical Research and Innovation (DRCI), University Hospital of Clermont-Ferrand (CHU), Clermont-Ferrand, France
| | - A Saraux
- Department of Rheumatology, Brest University Hospital, Brest, France
| | - C Richez
- Rheumatology Department, CHU Pellegrin, Bordeaux, France
| | - B Combe
- Département de Rhumatologie, CHU Montpellier, Université de Montpellier, Montpellier, France
| | - M Soubrier
- Rheumatology Department, CHU Gabriel Montpied, Clermont 1 University, Clermont-Ferrand, France
| |
Collapse
|
10
|
Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, Thys M, Henket M, Canivet G, Mathieu S, Eftaxia E, Lambin P, Tsoutzidis N, Miraglio B, Walsh S, Moutschen M, Louis R, Meunier P, Vos W, Leijenaar RTH, Lovinfosse P. Development and Validation of an Automated Radiomic CT Signature for Detecting COVID-19. Diagnostics (Basel) 2020; 11:E41. [PMID: 33396587 PMCID: PMC7823620 DOI: 10.3390/diagnostics11010041] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/22/2020] [Accepted: 12/23/2020] [Indexed: 12/28/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) outbreak has reached pandemic status. Drastic measures of social distancing are enforced in society and healthcare systems are being pushed to and beyond their limits. To help in the fight against this threat on human health, a fully automated AI framework was developed to extract radiomics features from volumetric chest computed tomography (CT) exams. The detection model was developed on a dataset of 1381 patients (181 COVID-19 patients plus 1200 non COVID control patients). A second, independent dataset of 197 RT-PCR confirmed COVID-19 patients and 500 control patients was used to assess the performance of the model. Diagnostic performance was assessed by the area under the receiver operating characteristic curve (AUC). The model had an AUC of 0.882 (95% CI: 0.851-0.913) in the independent test dataset (641 patients). The optimal decision threshold, considering the cost of false negatives twice as high as the cost of false positives, resulted in an accuracy of 85.18%, a sensitivity of 69.52%, a specificity of 91.63%, a negative predictive value (NPV) of 94.46% and a positive predictive value (PPV) of 59.44%. Benchmarked against RT-PCR confirmed cases of COVID-19, our AI framework can accurately differentiate COVID-19 from routine clinical conditions in a fully automated fashion. Thus, providing rapid accurate diagnosis in patients suspected of COVID-19 infection, facilitating the timely implementation of isolation procedures and early intervention.
Collapse
Affiliation(s)
- Julien Guiot
- Department of Pneumology, University Hospital of Liège, 4020 Liège, Belgium; (A.-N.F.); (M.H.); (R.L.)
| | - Akshayaa Vaidyanathan
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
- The D-Lab, Department of Precision Medicine, Maastricht University, 6229 Maastricht, The Netherlands;
| | - Louis Deprez
- Department of Radiology, University Hospital of Liège, 4020 Liège, Belgium; (L.D.); (D.D.); (E.E.); (P.M.)
| | - Fadila Zerka
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
- The D-Lab, Department of Precision Medicine, Maastricht University, 6229 Maastricht, The Netherlands;
| | - Denis Danthine
- Department of Radiology, University Hospital of Liège, 4020 Liège, Belgium; (L.D.); (D.D.); (E.E.); (P.M.)
| | - Anne-Noëlle Frix
- Department of Pneumology, University Hospital of Liège, 4020 Liège, Belgium; (A.-N.F.); (M.H.); (R.L.)
| | - Marie Thys
- Department of Medico-Economic Information, University Hospital of Liège, 4020 Liège, Belgium;
| | - Monique Henket
- Department of Pneumology, University Hospital of Liège, 4020 Liège, Belgium; (A.-N.F.); (M.H.); (R.L.)
| | - Gregory Canivet
- Department of Computer Applications, University Hospital of Liège, 4020 Liège, Belgium; (G.C.); (S.M.)
| | - Stephane Mathieu
- Department of Computer Applications, University Hospital of Liège, 4020 Liège, Belgium; (G.C.); (S.M.)
| | - Evanthia Eftaxia
- Department of Radiology, University Hospital of Liège, 4020 Liège, Belgium; (L.D.); (D.D.); (E.E.); (P.M.)
| | - Philippe Lambin
- The D-Lab, Department of Precision Medicine, Maastricht University, 6229 Maastricht, The Netherlands;
| | - Nathan Tsoutzidis
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
| | - Benjamin Miraglio
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
| | - Sean Walsh
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
| | - Michel Moutschen
- Department of Infectious Diseases, University Hospital of Liège, 4020 Liège, Belgium;
| | - Renaud Louis
- Department of Pneumology, University Hospital of Liège, 4020 Liège, Belgium; (A.-N.F.); (M.H.); (R.L.)
| | - Paul Meunier
- Department of Radiology, University Hospital of Liège, 4020 Liège, Belgium; (L.D.); (D.D.); (E.E.); (P.M.)
| | - Wim Vos
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
| | - Ralph T. H. Leijenaar
- Research and Development, Oncoradiomics SA, 4000 Liège, Belgium; (A.V.); (F.Z.); (N.T.); (B.M.); (S.W.); (W.V.); (R.T.H.L.)
| | - Pierre Lovinfosse
- Department of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, 4020 Liège, Belgium;
| |
Collapse
|
11
|
Dobos G, De Cevins C, Ly Ka So S, Jean-Louis F, Mathieu S, Ram-Wolff C, Resche-Rigon M, Bensussan A, Bagot M, Michel L. The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort. Br J Dermatol 2020; 185:405-411. [PMID: 33314029 DOI: 10.1111/bjd.19719] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 11/22/2020] [Accepted: 12/08/2020] [Indexed: 01/12/2023]
Abstract
BACKGROUND Clinical and histological diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF) is challenging in clinical routine. OBJECTIVES We investigated five blood markers previously described for SS (T-plastin, Twist, KIR3DL2, NKp46 and Tox) in a prospective validation cohort of patients. METHODS We included 447 patients in this study and 107 patients were followed up for prognosis. The markers were analysed by reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) on peripheral blood leucocytes and CD4+ T cells in a cohort of consecutive patients with early MF, erythrodermic MF and SS and compared with patients presenting with benign inflammatory dermatoses (BID) and erythrodermic BID. The markers were assessed in parallel to gold standard values such as CD4/CD8 ratio, loss of CD7 and CD26 membrane expression and CD4 absolute values. Sensitivity and specificity were analysed by receiver operator characteristic curves. The prognostic value of selected markers was analysed on a subset of patients. This study was conducted in one centre. RESULTS We defined cut-off values for each marker. T-plastin, Twist and KIR3DL2 had the best validity. SS may be overrepresented. The combination of T-plastin and Twist was able to differentiate between erythrodermic MF or BID and SS. The additional analysis of KIR3DL2 may be useful to predict the prognosis. CONCLUSIONS We propose T-plastin, Twist and KIR3DL2 measured by RT-qPCR as new diagnostic markers for Sézary syndrome.
Collapse
Affiliation(s)
- G Dobos
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - C De Cevins
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - S Ly Ka So
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - F Jean-Louis
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - S Mathieu
- Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - C Ram-Wolff
- Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - M Resche-Rigon
- SBIM, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - A Bensussan
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - M Bagot
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France.,Department of Dermatology, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| | - L Michel
- INSERM U976, Hôpital Saint Louis, APHP, 1 Avenue Claude Vellefaux, Paris, 75010, France
| |
Collapse
|
12
|
Podor R, Mendonça J, Lautru J, Brau HP, Nogues D, Candeias A, Horodysky P, Kolouch A, Barreau M, Carrier X, Ramenatte N, Mathieu S, Vilasi M. Evaluation and application of a new scintillator-based heat-resistant back-scattered electron detector during heat treatment in the scanning electron microscope. J Microsc 2020; 282:45-59. [PMID: 33216353 DOI: 10.1111/jmi.12979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 09/16/2020] [Accepted: 11/10/2020] [Indexed: 11/28/2022]
Abstract
A new high-temperature detector dedicated to the collection of backscattered electrons is used in combination with heating stages up to 1050°C, in high-vacuum and low-vacuum modes in order to evaluate its possibilities through signal-to-noise ration measurements and different applications. Four examples of material transformations occurring at high temperature are herein reported: grain growth during annealing of a rolled platinum foil, recrystallisation of a multiphased alloy, oxidation of a Ni-based alloy and complex phase transformations occurring during the annealing of an Al-Si coated boron steel. The detector could be potentially adapted to any type of SEM and it offers good opportunities to perform high-temperature experiments in various atmospheres.
Collapse
Affiliation(s)
- R Podor
- ICSM, Univ Montpellier, CNRS, ENSCM, CEA, Bagnols sur Cèze, France
| | - J Mendonça
- ICSM, Univ Montpellier, CNRS, ENSCM, CEA, Bagnols sur Cèze, France.,NewTEC Scientific, Nîmes, France
| | - J Lautru
- ICSM, Univ Montpellier, CNRS, ENSCM, CEA, Bagnols sur Cèze, France
| | - H P Brau
- ICSM, Univ Montpellier, CNRS, ENSCM, CEA, Bagnols sur Cèze, France
| | - D Nogues
- NewTEC Scientific, Nîmes, France
| | | | | | - A Kolouch
- CRYTUR, spol. s.r.o., Czech Republic
| | - M Barreau
- Laboratoire de Réactivité de Surface, CNRS, Sorbonne Université, Paris, France
| | - X Carrier
- Laboratoire de Réactivité de Surface, CNRS, Sorbonne Université, Paris, France
| | - N Ramenatte
- CNRS, IJL, Université de Lorraine, Nancy, France
| | - S Mathieu
- CNRS, IJL, Université de Lorraine, Nancy, France
| | - M Vilasi
- CNRS, IJL, Université de Lorraine, Nancy, France
| |
Collapse
|
13
|
Beal SJ, Wingrove T, Nause K, Lipstein E, Mathieu S, Greiner MV. The Role of Shared Decision-Making in Shaping Intent to Access Services for Adolescents in Protective Custody. Child Care Pract 2019; 25:64-78. [PMID: 31130815 PMCID: PMC6532998 DOI: 10.1080/13575279.2018.1521379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Including children in protective custody (e.g., foster care) in legal decisions positively impacts their perceptions of the legal system, with giving youth a voice being particularly important. Studies have primarily focused on including young people in legal processes; however, for adolescents in protective custody, decisions about living arrangements, education, and long-term planning are made outside the courtroom, with ramifications for young people and their perceptions of both legal and child protection systems. This study looks at such decision making using existing data from 151 adolescents who were ages 16-20 and had been in child welfare protective custody for at least 12 months. During in-person interviews we assessed their desired amount of involvement in a recent decision and their perceptions of their actual involvement. Youth named other individuals involved in decision-making. Data were coded and analysed to identify discrepancies in young people's perceptions of desired and actual levels of involvement. Results indicate that while the majority of adolescents (96%) are participating in decision-making, they generally desire more involvement in decisions made (64%). Only 7% of youth reported that their level of personal involvement and the involvement of others matched what they desired. The most common individuals identified in a decision made were child protection workers, legal professionals, and caregivers or family members. These findings enhance the existing literature by highlighting the unique issues related to giving young people in protective custody a voice, and provide an empirical foundation for guiding policies around who to involve in every-day decisions made for young people preparing for emancipation from protective custody.
Collapse
Affiliation(s)
- Sarah J Beal
- Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. USA
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH, 45267. USA
| | - Twila Wingrove
- Department of Psychology, Appalachian State University, 222 Joyce Lawrence Lane, Boone, NC 28608. USA
| | - Katie Nause
- Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. USA
| | - Ellen Lipstein
- Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. USA
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH, 45267. USA
| | - Stephane Mathieu
- Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. USA
| | - Mary V Greiner
- Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229. USA
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH, 45267. USA
| |
Collapse
|
14
|
Rousseau M, baumstarck K, Valkov M, Khaldi S, Laracca E, Mathieu S, Haddadou S, Ardati M, Teulade J, Felce A, Brisse C, Willocq D, Lenormand S, Auquier P, Billette de Villemeur T. Health issues in polyhandicapped patients according to age: Results of a large French survey. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Panzara M, Zhang J, Rinaldi C, McClorey G, Bowman K, Butler D, Dodart J, Frank-Kamenetsky M, Iwamoto N, Kothari N, Lu G, Mathieu S, M M, Melkonian M, Menon S, Standley S, Yang H, Zhong Z, Wood M, Vargeese C. Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Wood M, Zhang J, Bowman K, Butler D, Rinaldi C, McClorey G, Frank-Kamenetsky M, Iwamoto N, Kothari N, Lu G, Mathieu S, Meena M, Menon S, Shimizu M, Standley S, Yang H, Zhong Z, Francis C, Vargeese C. WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.442] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, Basem W, Battistella M, Marie-Cardine A, Vermeer M, Mathieu S, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Thonnart N, Widemann A, Bonin C, Sicard H, Paiva C, Pilz K, Kim Y. Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_31] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Bagot
- Dermatology; Hopital St Louis; Paris France
| | - P. Porcu
- Wexner Medical Center; Ohio State University; Columbus USA
| | | | - M. Khodadoust
- Oncology; Stanford University School of Medicine; Stanford USA
| | - W. Basem
- Wexner Medical Center; Ohio State University; Columbus USA
| | | | | | | | - S. Mathieu
- Dermatology; Hopital St Louis; Paris France
| | | | - M. Duvic
- Dermatology; MD Anderson Cancer Center; Houston USA
| | | | | | | | | | | | - C. Bonin
- R&D; Innate Pharma; Marseille France
| | - H. Sicard
- R&D; Innate Pharma; Marseille France
| | - C. Paiva
- R&D; Innate Pharma; Marseille France
| | - K. Pilz
- R&D; Innate Pharma; Marseille France
| | - Y.H. Kim
- Dermatology; Stanford Cancer Institute; Palo Alto USA
| |
Collapse
|
18
|
|
19
|
Ram-Wolff C, Brice P, Mathieu S, Vignon-Pennamen MD, Bagot M. Traitement par nivolumab d’un lymphome T helper folliculaire cutané : un premier cas. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Mathieu S, Ram-Wolff C, Beylot-Barry M, D’incan M, Oro S, Quéreux G, Chaby G, Aubin F, Wierzbicka Hainaut E, Skowron F, Bonnet N, Dereure O, Adamski H, Brunet-Possenti F, Bagot M. L’expérience française de l’usage du gel de chlorméthine pour le traitement du mycosis fongoïde : une série rétrospective de 107 cas du GFELC. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.166] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Louveaux Q, Mathei A, Mathieu S. Box search for the data mining of the key parameters of an industrial process. INTELL DATA ANAL 2016. [DOI: 10.3233/ida-150335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
22
|
Berthet E, De Rosa M, Vorilhon P, Soubrier M, Mathieu S. AB1073 Exploration of The Difficulties Encountered by General Practitioners with Methotrexate and Tnf-Inhibitor Treatment in Common Practice. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Daron C, Deschaumes C, Soubrier M, Mathieu S. THU0463 Viewpoints of Dental Surgeons on The Use of Bisphosphonates in Rheumatology Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Mourgues C, Soubrier M, Pereira B, Vorilhon P, Mathieu S. AB0829 2012 American Guidelines for The Management of Gout as Seen by Family Doctors in France. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Berthet E, De Rosa M, Lopez J, Vorilhon P, Soubrier M, Mathieu S. AB1072 General Practitioner Perceptions of Methotrexate and anti-TNF Treatments: A Qualitative Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Soubrier M, Pereira B, Tournadre A, Malochet-Guinamand S, Couderc M, Mathieu S, Tatar Z, Abdi D, Frayssac T, Fan A, Dubost JJ. FRI0186 Retention of First-Line anti-TNF Treatments and in Cases of Failure Retention Rates of anti-TNF Drug or A Non-TNF-Targeted Biologic in A Monocentric Cohort of 200 Rheumatoid Arthritis Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Partridge H, Perkins B, Mathieu S, Nicholls A, Adeniji K. Clinical recommendations in the management of the patient with type 1 diabetes on insulin pump therapy in the perioperative period: a primer for the anaesthetist. Br J Anaesth 2016; 116:18-26. [PMID: 26675948 DOI: 10.1093/bja/aev347] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Insulin pump therapy is increasingly common in patients with type 1 diabetes. Many of these patients will require surgery at some point in their lifetime. Few doctors will have experience of managing these patients, and little evidence exists to assist in the development of guidelines for patients with insulin pump therapy, undergoing surgery.It is clear that during emergency surgery insulin pump therapy is not appropriate and should be discontinued, but patients undergoing some elective surgery can and should continue insulin pump therapy, without any adverse effect on their blood sugar control, or on the outcome of their surgery. Individual hospitals need to formalize guidance on the management of patients receiving continuous subcutaneous insulin therapy, to allow patients the choice to continue their therapy during surgery. This expert opinion presents anaesthetists with a suggested clinical framework to help facilitate continued insulin pump therapy, during elective surgery and into the postoperative period.
Collapse
Affiliation(s)
- H Partridge
- Department of Diabetes and Endocrinology, Royal Bournemouth Hospital, Bournemouth, UK
| | - B Perkins
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada
| | - S Mathieu
- Department of Critical Care, Queen Alexandra Hospital, Portsmouth, UK
| | - A Nicholls
- Department of Diabetes and Endocrinology, Royal Bournemouth Hospital, Bournemouth, UK
| | - K Adeniji
- Department of Critical Care, Queen Alexandra Hospital, Portsmouth, UK
| |
Collapse
|
28
|
Lopez J, Tatar Z, Mathieu S, Tournadre A, Couderc M, Soubrier M, Dubost J. THU0250 Changes in the Efficiency of Infectious Spondylodiscitis Bacteriological Testing in the Last Twenty Years. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Tatar Z, Pereira B, Mathieu S, Malochet-Guinamand S, Guellec D, Nocturne G, Gossec L, Loeuille D, Soubrier M. FRI0243 Bone Mineral Density in Ankylosing Spondylitis: Meta-Analysis of Retrospective Observational Data from 3420 Subjects. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Tournadre A, Pereira B, Frayssac T, Tatar Z, Malochet-Guinamand S, Verny MA, Mathieu S, Couderc M, Dubost J, Soubrier M. SAT0098 Changes in Metabolic Profile During Treatment with Tocilizumab in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Rousseau MC, Mathieu S, Brisse C, Motawaj M, Grimont E, Auquier P, Billette de Villemeur T. Aetiologies, comorbidities and causes of death in a population of 133 patients with polyhandicaps cared for at specialist rehabilitation centres. Brain Inj 2015; 29:837-42. [DOI: 10.3109/02699052.2015.1004757] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
32
|
Mathieu S, Eveno C, Fourcade L, Faure Conter C, Sudour H, Rubie H, Habonimana E, Grapin C, Mansuy L, Sarnacki S, Orbach D, Gorde Grosjean S, Lopez Perrin K, Kalfa N, Plantaz D, Casagranda L, Lacour B, Berger C, Varlet F, Patural H, Stephan J. CO-45 – Tumeurs intra thoraciques du nouveau-né: une étude de 20 observations. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30146-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Hua C, Morel J, Ardouin E, Ricard E, Foret J, Mathieu S, Combe B, Lukas C. Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2015; 54:748-50. [DOI: 10.1093/rheumatology/keu531] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Fayet F, Savel C, Rodere M, Pereira B, Abdi D, Couderc M, Mathieu S, Tournadre A, Malochet-Guinamand S, Soubrier M, Dubost JJ. THU0574-HPR A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Nourrisson C, Mathieu S, Beytout J, Cambon M, Poirier P. Lésion ostéolytique chez une patiente splénectomisée : à propos d’un cas d’échinococcose alvéolaire vertébrale. Rev Med Interne 2014; 35:399-402. [DOI: 10.1016/j.revmed.2013.06.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 04/15/2013] [Accepted: 06/18/2013] [Indexed: 10/26/2022]
|
36
|
Soubrier M, Verny MA, Pereira B, Frayssac T, Couderc M, Malochet-Guinamand S, Tournadre A, Mathieu S, Dubost JJ. SAT0162 Assessment of Subclinical Atherosclerosis (Flow Mediated Dilatation and Arterial Stiffness) after 24 Weeks of Tocilizumab Therapy in 22 Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Mathieu S, Soubrier M. FRI0144 Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Rousseau MC, Mathieu S, Brisse C, Motawaj M, Grimont E, Auquier P, Billette de Villemeur T. Etiologies, comorbidities and causes of death in a population of 133 polyhandicapped patients cared for at specialist rehabilitation centres. Ann Phys Rehabil Med 2014. [DOI: 10.1016/j.rehab.2014.03.1237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Rousseau M, Mathieu S, Brisse C, Motawaj M, Grimont E, Auquier P, Billette de Villemeur T. Étiologies, comorbidités et causes de décès d’une population de 133 patients polyhandicapés pris en charge en SSR spécialisé. Ann Phys Rehabil Med 2014. [DOI: 10.1016/j.rehab.2014.03.1297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
|
41
|
Rousseau M, Mathieu S, Brisse C, Billette de Villemeur T. The health trajectory of the person in polyhandicap situation. Ann Phys Rehabil Med 2013. [DOI: 10.1016/j.rehab.2013.07.1087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Rousseau MC, Mathieu S, Brisse C, Motawaj M, Grimont E, Billette de Villemeur T. Aetiologies, morbidity and causes of death of a population of 133 patients with profound and multiple disabilities taken care in specialized hospitals. Ann Phys Rehabil Med 2013. [DOI: 10.1016/j.rehab.2013.07.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Mathieu S. [Being a family today - ethics for assisted reproductive techniques]. Gynecol Obstet Fertil 2013; 41:532-536. [PMID: 23958330 DOI: 10.1016/j.gyobfe.2013.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Accepted: 07/04/2013] [Indexed: 06/02/2023]
Abstract
Currently in France, all the children born as a result of an assisted reproduction procedure, represent 2.5% of all births. Although this proportion is not high, it is not to be neglected, particularly with regard to the sociological issues raised by assisted reproduction technologies (ART) - i.e. removing anonymity of gamete donation, post mortem insemination, ART access to single women and gay couples, surrogacy - to name four of the most prominent debates. What is new with ART is that a new therapeutic target of medicine is being developed, in other words procreation. Now it is no longer necessary for a man and a woman to resort to sex to have a child. This is a profound questioning of the representation of what appeared to be intangible, with some sort of divine aura. How, in this context, developing an ethics for ART? From a fethnographic field survey, we show here how this ethos of ART develops and how, therefore, we consider the multiple ways of being a family today.
Collapse
Affiliation(s)
- S Mathieu
- Département de sociologie, université de Lille-1, cité scientifique, 59100 Lille, France.
| |
Collapse
|
44
|
|
45
|
Couderc M, Mathieu S, Glace B, Soubrier M. AB1068 Efficacy of anakinra in pseudogout: Report of 3 cases. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Couderc M, Mathieu S, Pereira B, Schmidt J, Lesens O, Bonnet R, Al juhani F, Vayssade M, Glace B, Tournadre A, Malochet-guinamant S, Soubrier M, Dubost JJ. THU0435 Performance of the Usual Clinical and Biological Signs for the Diagnosis of Septic Arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Couderc M, Mathieu S, Soubrier M. AB0310 Predictive factors for the response to rituximab in rheumatoid arthritis: Results from a french university hospital. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 2013; 65:648-52. [PMID: 23045227 DOI: 10.1002/acr.21865] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Accepted: 09/25/2012] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To study the influence of several factors (rheumatoid factor [RF], anti-cyclic citrullinated peptide [anti-CCP], serum Ig level, and Epstein-Barr virus [EBV] load) on clinical response to rituximab (RTX) after 6 months in rheumatoid arthritis (RA) patients. METHODS Sixty-four patients receiving RTX (two 1-gm doses 2 weeks apart) for active RA were prospectively included. RF, anti-CCP, gamma globulin level, and EBV load were assessed prior to the first RTX cycle. Clinical responses were analyzed 6 months after RTX initiation using the European League Against Rheumatism criteria. Univariate and multivariate analyses were performed to identify factors associated with RTX response at 6 months. RESULTS The mean disease duration was 16.4 years and 46 patients (71.9%) had already received at least 1 anti-tumor necrosis factor agent prior to RTX. At 6 months, 46 patients (71.9%) had a good to moderate response to RTX. Anti-CCP positivity was associated with a good to moderate response (odds ratio [OR] 4, 95% confidence interval [95% CI] 1.04-15.5; P = 0.04). RF positivity (P = 0.26) and positive initial EBV load (P = 0.16) were not associated with a good to moderate response. Hyperimmunoglobulin was correlated with a poorer response to RTX than normal Ig levels (OR 0.04, 95% CI 0.005-0.28; P = 0.002). CONCLUSION Anti-CCP positivity was a predictor of good to moderate response to RTX in RA patients. On the other hand, high Ig levels were associated with a poorer outcome in contrast to previous findings. Further support from larger studies is necessary so as to optimize the management of the RA patients with high Ig levels.
Collapse
Affiliation(s)
- M Couderc
- CHU Gabriel Montpied, Clermont-Ferrand, France.
| | | | | | | | | |
Collapse
|
49
|
Petermans J, Mathieu S, Pincemail J, Seidel L, Defraigne J. Are there particular clinical and biological parameters that characterize nonagenarian patients hospitalized in geriatrics units (G.U.)? Eur Geriatr Med 2012. [DOI: 10.1016/j.eurger.2012.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Diamanti E, Mathieu S, Jeanneau C, Kitraki E, Panopoulos P, Spyrou G, About I. Endoplasmic reticulum stress and mineralization inhibition mechanism by the resinous monomer HEMA. Int Endod J 2012; 46:160-8. [DOI: 10.1111/j.1365-2591.2012.02103.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Accepted: 07/02/2012] [Indexed: 11/26/2022]
Affiliation(s)
- E. Diamanti
- Departments of Endodontics and Basic Sciences; Dental School; University of Athens; Athens Greece
- Biochemistry Division; Foundation for Biomedical Research; Academy of Athens; Athens Greece
| | - S. Mathieu
- INSERM UMR 911; CR02; Aix-Marseille Université; Marseille France
| | - C. Jeanneau
- Aix-Marseille Université; CNRS; ISM UMR 7287, 13288; Marseille cedex 09 France
| | - E. Kitraki
- Departments of Endodontics and Basic Sciences; Dental School; University of Athens; Athens Greece
| | - P. Panopoulos
- Departments of Endodontics and Basic Sciences; Dental School; University of Athens; Athens Greece
| | - G. Spyrou
- Biochemistry Division; Foundation for Biomedical Research; Academy of Athens; Athens Greece
| | - I. About
- Aix-Marseille Université; CNRS; ISM UMR 7287, 13288; Marseille cedex 09 France
| |
Collapse
|